John Keller

Dr John Keller joined Shionogi Inc. in July 2010 and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011.

Immediately prior to joining Shionogi, John was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, John served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, John had a 16-year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements originally establishing the Shionogi-GSK (later Shionogi-ViiV Healthcare) joint venture. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.

John holds a Ph.D. in microbiology from Rutgers University and a Bachelor's degree in biology from Johns Hopkins University.